https://www.wikidoc.org/index.php?title=Pulmonary_hypertension_Historical_Perspective&feed=atom&action=history
Pulmonary hypertension Historical Perspective - Revision history
2024-03-29T13:11:49Z
Revision history for this page on the wiki
MediaWiki 1.40.0
https://www.wikidoc.org/index.php?title=Pulmonary_hypertension_Historical_Perspective&diff=1456832&oldid=prev
Anmol Pitliya at 14:59, 27 March 2018
2018-03-27T14:59:04Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 14:59, 27 March 2018</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l27">Line 27:</td>
<td colspan="2" class="diff-lineno">Line 27:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{{reflist|2}}</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{{reflist|2}}</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">[[Category:Medicine]]</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">[[Category:Cardiology]]</ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Category:Pulmonology]]</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Category:Pulmonology]]</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>[[Category:<del style="font-weight: bold; text-decoration: none;">Cardiology</del>]]</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>[[Category:<ins style="font-weight: bold; text-decoration: none;">Emergency medicine</ins>]]</div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">[[Category:Up-To-Date]]</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{{WH}}</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{{WH}}</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{{WS}}</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{{WS}}</div></td></tr>
</table>
Anmol Pitliya
https://www.wikidoc.org/index.php?title=Pulmonary_hypertension_Historical_Perspective&diff=1456801&oldid=prev
Anmol Pitliya at 14:40, 27 March 2018
2018-03-27T14:40:15Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 14:40, 27 March 2018</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l4">Line 4:</td>
<td colspan="2" class="diff-lineno">Line 4:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Overview==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Overview==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>In 1891 a German physician Ernst von Romberg described pulmonary vascular sclerosis in an autopsy. In 1951 David Dresdale coined the term primary pulmonary hypertension for the first time. In 1951, David Dresdale coined the term primary pulmonary hypertension for the first time. In 1981, pulmonary hypertension registry landmark multi-center U.S. study characterizing natural history and clinical features of primary pulmonary hypertension (PPH).</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>In 1891<ins style="font-weight: bold; text-decoration: none;">, </ins>a German physician Ernst von Romberg described pulmonary vascular sclerosis in an autopsy. In 1951 David Dresdale coined the term primary pulmonary hypertension for the first time. In 1951, David Dresdale coined the term primary pulmonary hypertension for the first time. In 1981, pulmonary hypertension registry landmark multi-center U.S. study characterizing natural history and clinical features of primary pulmonary hypertension (PPH).</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Historical Perspective==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Historical Perspective==</div></td></tr>
</table>
Anmol Pitliya
https://www.wikidoc.org/index.php?title=Pulmonary_hypertension_Historical_Perspective&diff=1456800&oldid=prev
Anmol Pitliya at 14:39, 27 March 2018
2018-03-27T14:39:37Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 14:39, 27 March 2018</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l4">Line 4:</td>
<td colspan="2" class="diff-lineno">Line 4:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Overview==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Overview==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>In 1891 a German physician Ernst von Romberg described pulmonary vascular sclerosis in an autopsy. In 1951 David Dresdale coined the term primary pulmonary hypertension for the first time.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>In 1891 a German physician Ernst von Romberg described pulmonary vascular sclerosis in an autopsy. In 1951 David Dresdale coined the term primary pulmonary hypertension for the first time<ins style="font-weight: bold; text-decoration: none;">. In 1951, David Dresdale coined the term primary pulmonary hypertension for the first time. In 1981, pulmonary hypertension registry landmark multi-center U.S. study characterizing natural history and clinical features of primary pulmonary hypertension (PPH)</ins>.</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Historical Perspective==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Historical Perspective==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* The <del style="font-weight: bold; text-decoration: none;">Historical Perspective </del>of the PH is as follows:<ref name="pmid2700428">{{cite journal |vauthors=Smith DB |title=Continent diversions: an overview |journal=Dimens Oncol Nurs |volume=3 |issue=4 |pages=18–23 |date=1989 |pmid=2700428 |doi= |url=}}</ref><ref name="pmid14033007">{{cite journal |vauthors=KIRKENDALL WM, GIFFORD RW, HORWITZ D, WILSON WR, GOLDBERG LI, GROLLMAN A |title=General aspects of hypertension; past, present and future |journal=Postgrad Med |volume=34 |issue= |pages=150–6 |date=August 1963 |pmid=14033007 |doi= |url=}}</ref></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* The <ins style="font-weight: bold; text-decoration: none;">historical perspective </ins>of the PH is as follows:<ref name="pmid2700428">{{cite journal |vauthors=Smith DB |title=Continent diversions: an overview |journal=Dimens Oncol Nurs |volume=3 |issue=4 |pages=18–23 |date=1989 |pmid=2700428 |doi= |url=}}</ref><ref name="pmid14033007">{{cite journal |vauthors=KIRKENDALL WM, GIFFORD RW, HORWITZ D, WILSON WR, GOLDBERG LI, GROLLMAN A |title=General aspects of hypertension; past, present and future |journal=Postgrad Med |volume=34 |issue= |pages=150–6 |date=August 1963 |pmid=14033007 |doi= |url=}}</ref></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1891, a German physician Ernst von Romberg described pulmonary vascular sclerosis in an autopsy. </div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*</ins>* In 1891, a German physician Ernst von Romberg described pulmonary vascular sclerosis in an autopsy. </div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1901, Abel Ayerza Key lecture integrating cyanosis and right heart failure, named the condition as '''''cardiac negro'' - black heart.'''</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*</ins>* In 1901, Abel Ayerza Key lecture integrating cyanosis and right heart failure, named the condition as '''''cardiac negro'' - black heart.'''</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1913, F. C. Arrillaga, assigned syphilitic arteriosclerosis as etiology of PH; changed the name of disease to '''''Ayerza’s Disease.'''''</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*</ins>* In 1913, F. C. Arrillaga, assigned syphilitic arteriosclerosis as etiology of PH; changed the name of disease to '''''Ayerza’s Disease.'''''</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1929, Werner Forssman demonstrated that it was possible to perform [[Right heart catheterization|right sided catheterization]] in humans by performing [[catheterization]] on himself.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*</ins>* In 1929, Werner Forssman demonstrated that it was possible to perform [[Right heart catheterization|right sided catheterization]] in humans by performing [[catheterization]] on himself.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1951, David Dresdale coined the term primary pulmonary hypertension for the first time.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*</ins>* In 1951, David Dresdale coined the term primary pulmonary hypertension for the first time.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1956, Forssman, Cournand, and Richards were awarded the Nobel Prize for their contributions to the discovery of circulatory and cardiopulmonary systems.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*</ins>* In 1956, Forssman, Cournand, and Richards were awarded the Nobel Prize for their contributions to the discovery of circulatory and cardiopulmonary systems.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1958, Paul Wood published pulmonary hypertension with an association with a vasoconstrictive factor.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*</ins>* In 1958, Paul Wood published pulmonary hypertension with an association with a vasoconstrictive factor.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* During 1965–1970s, first pulmonary hypertension epidemic related to the approval of Aminorex.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*</ins>* During 1965–1970s, first pulmonary hypertension epidemic related to the approval of Aminorex.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1973, '''''1st WHO Meeting on pulmonary hypertension''''' the landmark meeting about pulmonary hypertension, provided recommendations for future directions.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*</ins>* In 1973, '''''1st WHO Meeting on pulmonary hypertension''''' the landmark meeting about pulmonary hypertension, provided recommendations for future directions.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1981, pulmonary hypertension registry landmark multi-center U.S. study characterizing natural history and clinical features of primary pulmonary hypertension (PPH).</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*</ins>* In 1981, pulmonary hypertension registry landmark multi-center U.S. study characterizing natural history and clinical features of primary pulmonary hypertension (PPH).</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1998, '''''2nd World Symposium on pulmonary hypertension,''''' formation of Evian Classification of pulmonary hypertension and the term pulmonary arterial hypertension (PAH) was coined.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*</ins>* In 1998, '''''2nd World Symposium on pulmonary hypertension,''''' formation of Evian Classification of pulmonary hypertension and the term pulmonary arterial hypertension (PAH) was coined.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 2003, '''''3rd World Symposium on pulmonary hypertension,''''' formation of Venice Classification; idiopathic PAH introduced to replace term PPH.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*</ins>* In 2003, '''''3rd World Symposium on pulmonary hypertension,''''' formation of Venice Classification; idiopathic PAH introduced to replace term PPH.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 2008, '''''4th World Symposium on pulmonary hypertension,''''' formation of Dana Point Classification; modification of genetic category, among others in Group 1.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*</ins>* In 2008, '''''4th World Symposium on pulmonary hypertension,''''' formation of Dana Point Classification; modification of genetic category, among others in Group 1.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 2013, '''''5th World Symposium on pulmonary hypertension,''''' formation of Nice Classification; further modifications of genetic category, among others in Group 1.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*</ins>* In 2013, '''''5th World Symposium on pulmonary hypertension,''''' formation of Nice Classification; further modifications of genetic category, among others in Group 1.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 2014, '''''International Right Heart Failure Foundation''''' - comprehensive nomenclature of RHF ([[right heart failure]]) defining distinction between [[right heart failure]] vs [[Right heart failure|right ventricular failure]] vs components of right heart system, and the definition of [[right heart failure]].</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*</ins>* In 2014, '''''International Right Heart Failure Foundation''''' - comprehensive nomenclature of RHF ([[right heart failure]]) defining distinction between [[right heart failure]] vs [[Right heart failure|right ventricular failure]] vs components of right heart system, and the definition of [[right heart failure]].</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==References==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==References==</div></td></tr>
</table>
Anmol Pitliya
https://www.wikidoc.org/index.php?title=Pulmonary_hypertension_Historical_Perspective&diff=1456761&oldid=prev
Anmol Pitliya at 13:38, 27 March 2018
2018-03-27T13:38:31Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 13:38, 27 March 2018</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l18">Line 18:</td>
<td colspan="2" class="diff-lineno">Line 18:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1973, '''''1st WHO Meeting on pulmonary hypertension''''' the landmark meeting about pulmonary hypertension, provided recommendations for future directions.</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1973, '''''1st WHO Meeting on pulmonary hypertension''''' the landmark meeting about pulmonary hypertension, provided recommendations for future directions.</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1981, pulmonary hypertension registry landmark multi-center U.S. study characterizing natural history and clinical features of primary pulmonary hypertension (PPH).</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1981, pulmonary hypertension registry landmark multi-center U.S. study characterizing natural history and clinical features of primary pulmonary hypertension (PPH).</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">* In 1996–1970s second Pulmonary Hypertension epidemic the association between anorexigens and pulmonary hypertension was first identified in the 1960s when an epidemic of PAH occurred in Europe that was linked to the anorexigens such as fenfluramine and dexfenfluramine.</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1998<ins style="font-weight: bold; text-decoration: none;">, </ins>'''''2nd World Symposium on pulmonary hypertension,''''' formation of Evian Classification of pulmonary hypertension and the term pulmonary arterial hypertension (PAH) was coined.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1998 '''''2nd World Symposium on pulmonary hypertension,''''' formation of Evian Classification of pulmonary hypertension and the term pulmonary arterial hypertension (PAH) was coined.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 2003<ins style="font-weight: bold; text-decoration: none;">, </ins>'''''3rd World Symposium on pulmonary hypertension,''''' formation of Venice Classification; idiopathic PAH introduced to replace term PPH.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 2003 '''''3rd World Symposium on pulmonary hypertension,''''' formation of Venice Classification; idiopathic PAH introduced to replace term PPH.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 2008<ins style="font-weight: bold; text-decoration: none;">, </ins>'''''4th World Symposium on pulmonary hypertension,''''' formation of Dana Point Classification; modification of genetic category, among others in Group 1.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 2008 '''''4th World Symposium on pulmonary hypertension,''''' formation of Dana Point Classification; modification of genetic category, among others in Group 1.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 2013<ins style="font-weight: bold; text-decoration: none;">, </ins>'''''5th World Symposium on pulmonary hypertension,''''' formation of Nice Classification; further modifications of genetic category, among others in Group 1.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 2013 '''''5th World Symposium on pulmonary hypertension,''''' formation of Nice Classification; further modifications of genetic category, among others in Group 1.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 2014<ins style="font-weight: bold; text-decoration: none;">, </ins>'''''International Right Heart Failure Foundation''''' - comprehensive nomenclature of RHF ([[right heart failure]]) defining distinction between [[right heart failure]] vs [[Right heart failure|right ventricular failure]] vs components of right heart system, and the definition of [[right heart failure]].</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 2014 '''''International Right Heart Failure Foundation''''' - comprehensive nomenclature of RHF ([[right heart failure]]) defining distinction between [[right heart failure]] vs [[Right heart failure|right ventricular failure]] vs components of right heart system, and the definition of [[right heart failure]].</div></td><td colspan="2" class="diff-side-added"></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==References==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==References==</div></td></tr>
</table>
Anmol Pitliya
https://www.wikidoc.org/index.php?title=Pulmonary_hypertension_Historical_Perspective&diff=1456619&oldid=prev
Anmol Pitliya at 19:07, 26 March 2018
2018-03-26T19:07:29Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 19:07, 26 March 2018</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l7">Line 7:</td>
<td colspan="2" class="diff-lineno">Line 7:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Historical Perspective==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Historical Perspective==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* The Historical Perspective of the PH is as follows:<ref name="pmid2700428">{{cite journal |vauthors=Smith DB |title=Continent diversions: an overview |journal=Dimens Oncol Nurs |volume=3 |issue=4 |pages=18–23 |date=1989 |pmid=2700428 |doi= |url=}}</ref><ref name="pmid14033007">{{cite journal |vauthors=KIRKENDALL WM, GIFFORD RW, HORWITZ D, WILSON WR, GOLDBERG LI, GROLLMAN A |title=General aspects of hypertension; past, present and future |journal=Postgrad Med |volume=34 |issue= |pages=150–6 |date=August 1963 |pmid=14033007 <del style="font-weight: bold; text-decoration: none;">|doi= |url=}}</ref><ref name="pmid">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid= </del>|doi= |url=}}</ref></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* The Historical Perspective of the PH is as follows:<ref name="pmid2700428">{{cite journal |vauthors=Smith DB |title=Continent diversions: an overview |journal=Dimens Oncol Nurs |volume=3 |issue=4 |pages=18–23 |date=1989 |pmid=2700428 |doi= |url=}}</ref><ref name="pmid14033007">{{cite journal |vauthors=KIRKENDALL WM, GIFFORD RW, HORWITZ D, WILSON WR, GOLDBERG LI, GROLLMAN A |title=General aspects of hypertension; past, present and future |journal=Postgrad Med |volume=34 |issue= |pages=150–6 |date=August 1963 |pmid=14033007 |doi= |url=}}</ref></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1891 a German physician Ernst von Romberg described pulmonary vascular sclerosis in an autopsy. </div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1891<ins style="font-weight: bold; text-decoration: none;">, </ins>a German physician Ernst von Romberg described pulmonary vascular sclerosis in an autopsy. </div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1901 Abel Ayerza Key lecture integrating cyanosis and right heart failure, named the condition as '''''cardiac negro'' -black heart.'''</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1901<ins style="font-weight: bold; text-decoration: none;">, </ins>Abel Ayerza Key lecture integrating cyanosis and right heart failure, named the condition as '''''cardiac negro'' - black heart.'''</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1913 F. C. Arrillaga <del style="font-weight: bold; text-decoration: none;">Syphilitic </del>arteriosclerosis <del style="font-weight: bold; text-decoration: none;">assigned </del>as etiology of PH; changed the name of disease to '''''Ayerza’s Disease.'''''</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1913<ins style="font-weight: bold; text-decoration: none;">, </ins>F. C. Arrillaga<ins style="font-weight: bold; text-decoration: none;">, assigned syphilitic </ins>arteriosclerosis as etiology of PH; changed the name of disease to '''''Ayerza’s Disease.'''''</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1929 Werner Forssman demonstrated that it was possible to perform right sided catheterization in humans by performing catheterization on himself.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1929<ins style="font-weight: bold; text-decoration: none;">, </ins>Werner Forssman demonstrated that it was possible to perform <ins style="font-weight: bold; text-decoration: none;">[[Right heart catheterization|</ins>right sided catheterization<ins style="font-weight: bold; text-decoration: none;">]] </ins>in humans by performing <ins style="font-weight: bold; text-decoration: none;">[[</ins>catheterization<ins style="font-weight: bold; text-decoration: none;">]] </ins>on himself.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1951 David Dresdale coined the term primary pulmonary hypertension for the first time.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1951<ins style="font-weight: bold; text-decoration: none;">, </ins>David Dresdale coined the term primary pulmonary hypertension for the first time.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1956 Forssman, Cournand, Richards were awarded the Nobel Prize for their contributions to the discovery of circulatory and cardiopulmonary systems.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1956<ins style="font-weight: bold; text-decoration: none;">, </ins>Forssman, Cournand, <ins style="font-weight: bold; text-decoration: none;">and </ins>Richards were awarded the Nobel Prize for their contributions to the discovery of circulatory and cardiopulmonary systems.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1958 Paul Wood <del style="font-weight: bold; text-decoration: none;">published Pulmonary Hypertension </del>with an association with a vasoconstrictive factor.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1958<ins style="font-weight: bold; text-decoration: none;">, </ins>Paul Wood <ins style="font-weight: bold; text-decoration: none;">published pulmonary hypertension </ins>with an association with a vasoconstrictive factor.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* <del style="font-weight: bold; text-decoration: none;">In </del>1965–1970s first <del style="font-weight: bold; text-decoration: none;">Pulmonary Hypertension </del>epidemic related to the approval of Aminorex.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* <ins style="font-weight: bold; text-decoration: none;">During </ins>1965–1970s<ins style="font-weight: bold; text-decoration: none;">, </ins>first <ins style="font-weight: bold; text-decoration: none;">pulmonary hypertension </ins>epidemic related to the approval of Aminorex.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1973 '''''1st WHO Meeting <del style="font-weight: bold; text-decoration: none;">in PH</del>''''' the landmark meeting about <del style="font-weight: bold; text-decoration: none;">Pulmonary Hypertension</del>, provided recommendations for future directions</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1973<ins style="font-weight: bold; text-decoration: none;">, </ins>'''''1st WHO Meeting <ins style="font-weight: bold; text-decoration: none;">on pulmonary hypertension</ins>''''' the landmark meeting about <ins style="font-weight: bold; text-decoration: none;">pulmonary hypertension</ins>, provided recommendations for future directions<ins style="font-weight: bold; text-decoration: none;">.</ins></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1981 <del style="font-weight: bold; text-decoration: none;">Pulmonary Hypertension </del>registry landmark multi-center U.S. study characterizing natural history and clinical features of PPH.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1981<ins style="font-weight: bold; text-decoration: none;">, pulmonary hypertension </ins>registry landmark multi-center U.S. study characterizing natural history and clinical features of <ins style="font-weight: bold; text-decoration: none;">primary pulmonary hypertension (</ins>PPH<ins style="font-weight: bold; text-decoration: none;">)</ins>.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1996–1970s second Pulmonary Hypertension epidemic the association between anorexigens and <del style="font-weight: bold; text-decoration: none;">PH </del>was first identified in the 1960s when an epidemic of PAH occurred in Europe that was linked to the anorexigens such as fenfluramine and dexfenfluramine.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1996–1970s second Pulmonary Hypertension epidemic the association between anorexigens and <ins style="font-weight: bold; text-decoration: none;">pulmonary hypertension </ins>was first identified in the 1960s when an epidemic of PAH occurred in Europe that was linked to the anorexigens such as fenfluramine and dexfenfluramine.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1998 '''''2nd World Symposium on <del style="font-weight: bold; text-decoration: none;">PH</del>''''' formation of Evian Classification of <del style="font-weight: bold; text-decoration: none;">PH </del>and the term pulmonary arterial hypertension (PAH) was coined.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1998 '''''2nd World Symposium on <ins style="font-weight: bold; text-decoration: none;">pulmonary hypertension,</ins>''''' formation of Evian Classification of <ins style="font-weight: bold; text-decoration: none;">pulmonary hypertension </ins>and the term pulmonary arterial hypertension (PAH) was coined.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 2003 '''''3rd World Symposium on <del style="font-weight: bold; text-decoration: none;">PH</del>''''' Venice Classification; idiopathic PAH introduced to replace term PPH</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 2003 '''''3rd World Symposium on <ins style="font-weight: bold; text-decoration: none;">pulmonary hypertension,</ins>''''' <ins style="font-weight: bold; text-decoration: none;">formation of </ins>Venice Classification; idiopathic PAH introduced to replace term PPH<ins style="font-weight: bold; text-decoration: none;">.</ins></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 2008 '''''4th World Symposium on <del style="font-weight: bold; text-decoration: none;">PH</del>''''' Dana Point Classification; modification of genetic category, among others in Group 1</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 2008 '''''4th World Symposium on <ins style="font-weight: bold; text-decoration: none;">pulmonary hypertension,</ins>''''' <ins style="font-weight: bold; text-decoration: none;">formation of </ins>Dana Point Classification; modification of genetic category, among others in Group 1<ins style="font-weight: bold; text-decoration: none;">.</ins></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 2013 '''''5th World Symposium on <del style="font-weight: bold; text-decoration: none;">PH</del>''''' Nice Classification; further modifications of genetic category, among others in Group 1</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 2013 '''''5th World Symposium on <ins style="font-weight: bold; text-decoration: none;">pulmonary hypertension,</ins>''''' <ins style="font-weight: bold; text-decoration: none;">formation of </ins>Nice Classification; further modifications of genetic category, among others in Group 1<ins style="font-weight: bold; text-decoration: none;">.</ins></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 2014 '''''International Right Heart Failure Foundation'''''- comprehensive nomenclature of RHF (<del style="font-weight: bold; text-decoration: none;">Right Heart Failure</del>) defining distinction between right heart failure vs right ventricular failure vs components of right heart system, and the definition of right heart failure</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 2014 '''''International Right Heart Failure Foundation''''' - comprehensive nomenclature of RHF (<ins style="font-weight: bold; text-decoration: none;">[[right heart failure]]</ins>) defining distinction between <ins style="font-weight: bold; text-decoration: none;">[[</ins>right heart failure<ins style="font-weight: bold; text-decoration: none;">]] </ins>vs <ins style="font-weight: bold; text-decoration: none;">[[Right heart failure|</ins>right ventricular failure<ins style="font-weight: bold; text-decoration: none;">]] </ins>vs components of right heart system, and the definition of <ins style="font-weight: bold; text-decoration: none;">[[</ins>right heart failure<ins style="font-weight: bold; text-decoration: none;">]].</ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==References==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==References==</div></td></tr>
</table>
Anmol Pitliya
https://www.wikidoc.org/index.php?title=Pulmonary_hypertension_Historical_Perspective&diff=1450344&oldid=prev
Ajay Gade at 19:15, 1 March 2018
2018-03-01T19:15:06Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 19:15, 1 March 2018</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l9">Line 9:</td>
<td colspan="2" class="diff-lineno">Line 9:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* The Historical Perspective of the PH is as follows:<ref name="pmid2700428">{{cite journal |vauthors=Smith DB |title=Continent diversions: an overview |journal=Dimens Oncol Nurs |volume=3 |issue=4 |pages=18–23 |date=1989 |pmid=2700428 |doi= |url=}}</ref><ref name="pmid14033007">{{cite journal |vauthors=KIRKENDALL WM, GIFFORD RW, HORWITZ D, WILSON WR, GOLDBERG LI, GROLLMAN A |title=General aspects of hypertension; past, present and future |journal=Postgrad Med |volume=34 |issue= |pages=150–6 |date=August 1963 |pmid=14033007 |doi= |url=}}</ref><ref name="pmid">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid= |doi= |url=}}</ref></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* The Historical Perspective of the PH is as follows:<ref name="pmid2700428">{{cite journal |vauthors=Smith DB |title=Continent diversions: an overview |journal=Dimens Oncol Nurs |volume=3 |issue=4 |pages=18–23 |date=1989 |pmid=2700428 |doi= |url=}}</ref><ref name="pmid14033007">{{cite journal |vauthors=KIRKENDALL WM, GIFFORD RW, HORWITZ D, WILSON WR, GOLDBERG LI, GROLLMAN A |title=General aspects of hypertension; past, present and future |journal=Postgrad Med |volume=34 |issue= |pages=150–6 |date=August 1963 |pmid=14033007 |doi= |url=}}</ref><ref name="pmid">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid= |doi= |url=}}</ref></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1891 a German physician Ernst von Romberg described pulmonary vascular sclerosis in an autopsy. </div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1891 a German physician Ernst von Romberg described pulmonary vascular sclerosis in an autopsy. </div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1901 Abel Ayerza Key lecture integrating cyanosis and right heart failure, named the condition as <del style="font-weight: bold; text-decoration: none;">“cardiac negro”</del>-black heart.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1901 Abel Ayerza Key lecture integrating cyanosis and right heart failure, named the condition as <ins style="font-weight: bold; text-decoration: none;">'''''cardiac negro'' </ins>-black heart.<ins style="font-weight: bold; text-decoration: none;">'''</ins></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1913 F. C. Arrillaga Syphilitic arteriosclerosis assigned as etiology of PH; changed the name of disease to <del style="font-weight: bold; text-decoration: none;">“Ayerza’s Disease”</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1913 F. C. Arrillaga Syphilitic arteriosclerosis assigned as etiology of PH; changed the name of disease to <ins style="font-weight: bold; text-decoration: none;">'''''Ayerza’s Disease.'''''</ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1929 Werner Forssman demonstrated that it was possible to perform right sided catheterization in humans by performing catheterization on himself.</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1929 Werner Forssman demonstrated that it was possible to perform right sided catheterization in humans by performing catheterization on himself.</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1951 David Dresdale coined the term primary pulmonary hypertension for the first time.</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1951 David Dresdale coined the term primary pulmonary hypertension for the first time.</div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l16">Line 16:</td>
<td colspan="2" class="diff-lineno">Line 16:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1958 Paul Wood published Pulmonary Hypertension with an association with a vasoconstrictive factor.</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1958 Paul Wood published Pulmonary Hypertension with an association with a vasoconstrictive factor.</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1965–1970s first Pulmonary Hypertension epidemic related to the approval of Aminorex.</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1965–1970s first Pulmonary Hypertension epidemic related to the approval of Aminorex.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1973 1st WHO Meeting in PH the landmark meeting about Pulmonary Hypertension, provided recommendations for future directions</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1973 <ins style="font-weight: bold; text-decoration: none;">'''''</ins>1st WHO Meeting in PH<ins style="font-weight: bold; text-decoration: none;">''''' </ins>the landmark meeting about Pulmonary Hypertension, provided recommendations for future directions</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1981 <del style="font-weight: bold; text-decoration: none;">PPH Registry </del>landmark multi-center U.S. study characterizing natural history and clinical features of PPH.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1981 <ins style="font-weight: bold; text-decoration: none;">Pulmonary Hypertension registry </ins>landmark multi-center U.S. study characterizing natural history and clinical features of PPH.</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1996–1970s second Pulmonary Hypertension epidemic the association between anorexigens and PH was first identified in the 1960s when an epidemic of PAH occurred in Europe that was linked to the anorexigens such as fenfluramine and dexfenfluramine.</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1996–1970s second Pulmonary Hypertension epidemic the association between anorexigens and PH was first identified in the 1960s when an epidemic of PAH occurred in Europe that was linked to the anorexigens such as fenfluramine and dexfenfluramine.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1998 2nd World Symposium on PH formation of Evian Classification of PH and the term pulmonary arterial hypertension (PAH) was coined.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1998 <ins style="font-weight: bold; text-decoration: none;">'''''</ins>2nd World Symposium on PH<ins style="font-weight: bold; text-decoration: none;">''''' </ins>formation of Evian Classification of PH and the term pulmonary arterial hypertension (PAH) was coined.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 2003 3rd World Symposium on PH Venice Classification; idiopathic PAH introduced to replace term PPH</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 2003 <ins style="font-weight: bold; text-decoration: none;">'''''</ins>3rd World Symposium on PH<ins style="font-weight: bold; text-decoration: none;">''''' </ins>Venice Classification; idiopathic PAH introduced to replace term PPH</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 2008 4th World Symposium on PH Dana Point Classification; modification of genetic category, among others in Group 1</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 2008 <ins style="font-weight: bold; text-decoration: none;">'''''</ins>4th World Symposium on PH<ins style="font-weight: bold; text-decoration: none;">''''' </ins>Dana Point Classification; modification of genetic category, among others in Group 1</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 2013 5th World Symposium on PH Nice Classification; further modifications of genetic category, among others in Group 1</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 2013 <ins style="font-weight: bold; text-decoration: none;">'''''</ins>5th World Symposium on PH<ins style="font-weight: bold; text-decoration: none;">''''' </ins>Nice Classification; further modifications of genetic category, among others in Group 1</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 2014 International Right Heart Failure Foundation- comprehensive nomenclature of RHF (Right Heart Failure) defining distinction between right heart failure vs right ventricular failure vs components of right heart system, and the definition of right heart failure</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 2014 <ins style="font-weight: bold; text-decoration: none;">'''''</ins>International Right Heart Failure Foundation<ins style="font-weight: bold; text-decoration: none;">'''''</ins>- comprehensive nomenclature of RHF (Right Heart Failure) defining distinction between right heart failure vs right ventricular failure vs components of right heart system, and the definition of right heart failure</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==References==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==References==</div></td></tr>
</table>
Ajay Gade
https://www.wikidoc.org/index.php?title=Pulmonary_hypertension_Historical_Perspective&diff=1450342&oldid=prev
Ajay Gade: /* Historical Perspective */
2018-03-01T19:12:27Z
<p><span dir="auto"><span class="autocomment">Historical Perspective</span></span></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 19:12, 1 March 2018</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l9">Line 9:</td>
<td colspan="2" class="diff-lineno">Line 9:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* The Historical Perspective of the PH is as follows:<ref name="pmid2700428">{{cite journal |vauthors=Smith DB |title=Continent diversions: an overview |journal=Dimens Oncol Nurs |volume=3 |issue=4 |pages=18–23 |date=1989 |pmid=2700428 |doi= |url=}}</ref><ref name="pmid14033007">{{cite journal |vauthors=KIRKENDALL WM, GIFFORD RW, HORWITZ D, WILSON WR, GOLDBERG LI, GROLLMAN A |title=General aspects of hypertension; past, present and future |journal=Postgrad Med |volume=34 |issue= |pages=150–6 |date=August 1963 |pmid=14033007 |doi= |url=}}</ref><ref name="pmid">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid= |doi= |url=}}</ref></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* The Historical Perspective of the PH is as follows:<ref name="pmid2700428">{{cite journal |vauthors=Smith DB |title=Continent diversions: an overview |journal=Dimens Oncol Nurs |volume=3 |issue=4 |pages=18–23 |date=1989 |pmid=2700428 |doi= |url=}}</ref><ref name="pmid14033007">{{cite journal |vauthors=KIRKENDALL WM, GIFFORD RW, HORWITZ D, WILSON WR, GOLDBERG LI, GROLLMAN A |title=General aspects of hypertension; past, present and future |journal=Postgrad Med |volume=34 |issue= |pages=150–6 |date=August 1963 |pmid=14033007 |doi= |url=}}</ref><ref name="pmid">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid= |doi= |url=}}</ref></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1891 a German physician Ernst von Romberg described pulmonary vascular sclerosis in an autopsy. </div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1891 a German physician Ernst von Romberg described pulmonary vascular sclerosis in an autopsy. </div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1901 Abel Ayerza Key lecture integrating cyanosis and right heart failure, named the condition as “cardiac negro” <del style="font-weight: bold; text-decoration: none;">(</del>black <del style="font-weight: bold; text-decoration: none;">cardiac)</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1901 Abel Ayerza Key lecture integrating cyanosis and right heart failure, named the condition as “cardiac negro”<ins style="font-weight: bold; text-decoration: none;">-</ins>black <ins style="font-weight: bold; text-decoration: none;">heart.</ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1913 F. C. Arrillaga Syphilitic arteriosclerosis assigned as etiology of PH; changed the name of disease to “Ayerza’s Disease”</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1913 F. C. Arrillaga Syphilitic arteriosclerosis assigned as etiology of PH; changed the name of disease to “Ayerza’s Disease”</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1929 Werner Forssman demonstrated that it was possible to perform right sided catheterization in humans by performing catheterization on himself</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1929 Werner Forssman demonstrated that it was possible to perform right sided catheterization in humans by performing catheterization on himself<ins style="font-weight: bold; text-decoration: none;">.</ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1951 David Dresdale coined the term primary pulmonary hypertension for the first time.</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1951 David Dresdale coined the term primary pulmonary hypertension for the first time.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1956 Forssman, Cournand, Richards awarded Nobel Prize for their contributions to the discovery of circulatory and cardiopulmonary systems</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1956 Forssman, Cournand, Richards <ins style="font-weight: bold; text-decoration: none;">were </ins>awarded <ins style="font-weight: bold; text-decoration: none;">the </ins>Nobel Prize for their contributions to the discovery of circulatory and cardiopulmonary systems<ins style="font-weight: bold; text-decoration: none;">.</ins></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1958 Paul Wood published Pulmonary Hypertension with <del style="font-weight: bold; text-decoration: none;">special reference to the Vasoconstrictive Factor</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1958 Paul Wood published Pulmonary Hypertension with <ins style="font-weight: bold; text-decoration: none;">an association with a vasoconstrictive factor.</ins></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1965–1970s <del style="font-weight: bold; text-decoration: none;">First PPH </del>epidemic related to the approval of Aminorex.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1965–1970s <ins style="font-weight: bold; text-decoration: none;">first Pulmonary Hypertension </ins>epidemic related to the approval of Aminorex.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1973 1st WHO Meeting in PH the landmark meeting about <del style="font-weight: bold; text-decoration: none;">PPH; </del>provided recommendations for future directions</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1973 1st WHO Meeting in PH the landmark meeting about <ins style="font-weight: bold; text-decoration: none;">Pulmonary Hypertension, </ins>provided recommendations for future directions</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1981 PPH Registry landmark multi-center U.S. study characterizing natural history and clinical features of PPH</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1981 PPH Registry landmark multi-center U.S. study characterizing natural history and clinical features of PPH<ins style="font-weight: bold; text-decoration: none;">.</ins></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1996–1970s <del style="font-weight: bold; text-decoration: none;">Second PPH </del>epidemic the association between anorexigens and PH was first identified in the 1960s when an epidemic of PAH occurred in Europe that was linked to the anorexigens such as fenfluramine and dexfenfluramine.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1996–1970s <ins style="font-weight: bold; text-decoration: none;">second Pulmonary Hypertension </ins>epidemic the association between anorexigens and PH was first identified in the 1960s when an epidemic of PAH occurred in Europe that was linked to the anorexigens such as fenfluramine and dexfenfluramine.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1998 2nd World Symposium on PH formation of Evian Classification of PH<del style="font-weight: bold; text-decoration: none;">; introduction of </del>term <del style="font-weight: bold; text-decoration: none;">“pulmonary </del>arterial <del style="font-weight: bold; text-decoration: none;">hypertension”, </del>PAH</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1998 2nd World Symposium on PH formation of Evian Classification of PH <ins style="font-weight: bold; text-decoration: none;">and the </ins>term <ins style="font-weight: bold; text-decoration: none;">pulmonary </ins>arterial <ins style="font-weight: bold; text-decoration: none;">hypertension (</ins>PAH<ins style="font-weight: bold; text-decoration: none;">) was coined.</ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 2003 3rd World Symposium on PH Venice Classification; idiopathic PAH introduced to replace term PPH</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 2003 3rd World Symposium on PH Venice Classification; idiopathic PAH introduced to replace term PPH</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 2008 4th World Symposium on PH Dana Point Classification; modification of genetic category, among others in Group 1</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 2008 4th World Symposium on PH Dana Point Classification; modification of genetic category, among others in Group 1</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 2013 5th World Symposium on PH Nice Classification; further modifications of genetic category, among others in Group 1</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 2013 5th World Symposium on PH Nice Classification; further modifications of genetic category, among others in Group 1</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 2014 International Right Heart Failure Foundation <del style="font-weight: bold; text-decoration: none;">Working Group development of a </del>comprehensive nomenclature of <del style="font-weight: bold; text-decoration: none;">right heart failure: </del>defining distinction between right heart failure <del style="font-weight: bold; text-decoration: none;">and </del>right ventricular failure<del style="font-weight: bold; text-decoration: none;">, </del>components of right heart system, and definition of right heart failure</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 2014 International Right Heart Failure Foundation<ins style="font-weight: bold; text-decoration: none;">- </ins>comprehensive nomenclature of <ins style="font-weight: bold; text-decoration: none;">RHF (Right Heart Failure) </ins>defining distinction between right heart failure <ins style="font-weight: bold; text-decoration: none;">vs </ins>right ventricular failure <ins style="font-weight: bold; text-decoration: none;">vs </ins>components of right heart system, and <ins style="font-weight: bold; text-decoration: none;">the </ins>definition of right heart failure</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==References==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==References==</div></td></tr>
</table>
Ajay Gade
https://www.wikidoc.org/index.php?title=Pulmonary_hypertension_Historical_Perspective&diff=1450327&oldid=prev
Ajay Gade at 19:04, 1 March 2018
2018-03-01T19:04:24Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 19:04, 1 March 2018</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l4">Line 4:</td>
<td colspan="2" class="diff-lineno">Line 4:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Overview==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Overview==</div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">In 1891 a German physician Ernst von Romberg described pulmonary vascular sclerosis in an autopsy. In 1951 David Dresdale coined the term primary pulmonary hypertension for the first time.</ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Historical Perspective==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Historical Perspective==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* The Historical Perspective of the PH is as follows:<ref name="pmid2700428">{{cite journal |vauthors=Smith DB |title=Continent diversions: an overview |journal=Dimens Oncol Nurs |volume=3 |issue=4 |pages=18–23 |date=1989 |pmid=2700428 |doi= |url=}}</ref></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* The Historical Perspective of the PH is as follows:<ref name="pmid2700428">{{cite journal |vauthors=Smith DB |title=Continent diversions: an overview |journal=Dimens Oncol Nurs |volume=3 |issue=4 |pages=18–23 |date=1989 |pmid=2700428 <ins style="font-weight: bold; text-decoration: none;">|doi= |url=}}</ref><ref name="pmid14033007">{{cite journal |vauthors=KIRKENDALL WM, GIFFORD RW, HORWITZ D, WILSON WR, GOLDBERG LI, GROLLMAN A |title=General aspects of hypertension; past, present and future |journal=Postgrad Med |volume=34 |issue= |pages=150–6 |date=August 1963 |pmid=14033007 |doi= |url=}}</ref><ref name="pmid">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid= </ins>|doi= |url=}}</ref></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1891 a German physician Ernst von Romberg<del style="font-weight: bold; text-decoration: none;">, </del>described pulmonary vascular sclerosis in an autopsy. </div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1891 a German physician Ernst von Romberg described pulmonary vascular sclerosis in an autopsy. </div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1901 Abel Ayerza Key lecture integrating cyanosis and right heart failure, named the condition as “cardiac negro” (black cardiac)</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1901 Abel Ayerza Key lecture integrating cyanosis and right heart failure, named the condition as “cardiac negro” (black cardiac)</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1913 F. C. Arrillaga Syphilitic arteriosclerosis assigned as etiology of PH; changed the name of disease to “Ayerza’s Disease”</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1913 F. C. Arrillaga Syphilitic arteriosclerosis assigned as etiology of PH; changed the name of disease to “Ayerza’s Disease”</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1929 Werner Forssman demonstrated that it was possible to perform right sided catheterization in humans by performing catheterization on himself</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1929 Werner Forssman demonstrated that it was possible to perform right sided catheterization in humans by performing catheterization on himself</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1951 David Dresdale coined the term <del style="font-weight: bold; text-decoration: none;">“primary </del>pulmonary <del style="font-weight: bold; text-decoration: none;">hypertension”, PPH </del>for the first time.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1951 David Dresdale coined the term <ins style="font-weight: bold; text-decoration: none;">primary </ins>pulmonary <ins style="font-weight: bold; text-decoration: none;">hypertension </ins>for the first time.</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1956 Forssman, Cournand, Richards awarded Nobel Prize for their contributions to the discovery of circulatory and cardiopulmonary systems</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1956 Forssman, Cournand, Richards awarded Nobel Prize for their contributions to the discovery of circulatory and cardiopulmonary systems</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1958 Paul Wood published Pulmonary Hypertension with <del style="font-weight: bold; text-decoration: none;">Special Reference </del>to the Vasoconstrictive Factor</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1958 Paul Wood published Pulmonary Hypertension with <ins style="font-weight: bold; text-decoration: none;">special reference </ins>to the Vasoconstrictive Factor</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1965–1970s First PPH <del style="font-weight: bold; text-decoration: none;">Epidemic Related </del>to approval of Aminorex<del style="font-weight: bold; text-decoration: none;">, </del>.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1965–1970s First PPH <ins style="font-weight: bold; text-decoration: none;">epidemic related </ins>to <ins style="font-weight: bold; text-decoration: none;">the </ins>approval of Aminorex.</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1973 1st WHO Meeting in PH the landmark meeting about PPH; provided recommendations for future directions</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1973 1st WHO Meeting in PH the landmark meeting about PPH; provided recommendations for future directions</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1981 PPH Registry landmark multi-center U.S. study characterizing natural history and clinical features of PPH</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1981 PPH Registry landmark multi-center U.S. study characterizing natural history and clinical features of PPH</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 1996–1970s Second PPH <del style="font-weight: bold; text-decoration: none;">Epidemic </del>the association between anorexigens and PH was first identified in the 1960s when an epidemic of PAH occurred in Europe that was linked to the anorexigens such as fenfluramine and dexfenfluramine .</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 1996–1970s Second PPH <ins style="font-weight: bold; text-decoration: none;">epidemic </ins>the association between anorexigens and PH was first identified in the 1960s when an epidemic of PAH occurred in Europe that was linked to the anorexigens such as fenfluramine and dexfenfluramine.</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1998 2nd World Symposium on PH formation of Evian Classification of PH; introduction of term “pulmonary arterial hypertension”, PAH</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 1998 2nd World Symposium on PH formation of Evian Classification of PH; introduction of term “pulmonary arterial hypertension”, PAH</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* In 2003 3rd World Symposium on PH <del style="font-weight: bold; text-decoration: none;">venice </del>Classification; idiopathic PAH introduced to replace term PPH</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* In 2003 3rd World Symposium on PH <ins style="font-weight: bold; text-decoration: none;">Venice </ins>Classification; idiopathic PAH introduced to replace term PPH</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 2008 4th World Symposium on PH Dana Point Classification; modification of genetic category, among others in Group 1</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 2008 4th World Symposium on PH Dana Point Classification; modification of genetic category, among others in Group 1</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 2013 5th World Symposium on PH Nice Classification; further modifications of genetic category, among others in Group 1</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* In 2013 5th World Symposium on PH Nice Classification; further modifications of genetic category, among others in Group 1</div></td></tr>
</table>
Ajay Gade
https://www.wikidoc.org/index.php?title=Pulmonary_hypertension_Historical_Perspective&diff=1450322&oldid=prev
Ajay Gade: /* Historical Perspective */
2018-03-01T19:00:14Z
<p><span dir="auto"><span class="autocomment">Historical Perspective</span></span></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 19:00, 1 March 2018</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l6">Line 6:</td>
<td colspan="2" class="diff-lineno">Line 6:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Historical Perspective==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Historical Perspective==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>The <del style="font-weight: bold; text-decoration: none;">incidence </del>of <del style="font-weight: bold; text-decoration: none;">PAH associated with anorexigens </del>is <del style="font-weight: bold; text-decoration: none;">cyclical in nature and varies depending on the availability of specific appetite suppressants. The link was first identified in the 1960s when an epidemic of PAH occurred in Switzerland, Austria and Germany that was linked to the anorexigen aminorex fumarate. Use of the anorexigens fenfluramine and dexfenfluramine have also been linked with </del>an <del style="font-weight: bold; text-decoration: none;">increased risk for PAH.</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* </ins>The <ins style="font-weight: bold; text-decoration: none;">Historical Perspective </ins>of <ins style="font-weight: bold; text-decoration: none;">the PH </ins>is <ins style="font-weight: bold; text-decoration: none;">as follows:<ref name="pmid2700428">{{cite journal |vauthors=Smith DB |title=Continent diversions: </ins>an <ins style="font-weight: bold; text-decoration: none;">overview |journal=Dimens Oncol Nurs |volume=</ins>3 <ins style="font-weight: bold; text-decoration: none;">|issue=4 |pages=18–23 |date=1989 |pmid=2700428 |doi= |url=}}</ref></ins></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* In 1891 a German physician </ins>Ernst von Romberg, described <ins style="font-weight: bold; text-decoration: none;">pulmonary vascular sclerosis in </ins>an autopsy. </div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Prior to the development of disease-specific targeted PAH therapies, the median survival for subjects diagnosed with IPAH was approximately 2.8 years. However, 2.8 years likely underestimates current survival as the course of the disease has been favorably altered by therapeutic advances since that report from the 1980s. Prognosis is also dependent on the underlying etiology of the disease. The prognosis for patients with PAH associated with connective tissue disease appears to be worse than for those with IPAH. Estimates for 2-year survival in scleroderma patients with associated PAH are 40% compared with 48% for </del>3<del style="font-weight: bold; text-decoration: none;">-year survival in patients with IPAH. Survival in patients with HIV-associated PAH is similar to patients with IPAH. With current HIV therapies, most of the deaths in patients with HIV and associated PAH are now attributed to PAH.</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* </ins>In <ins style="font-weight: bold; text-decoration: none;">1901 Abel Ayerza Key lecture integrating cyanosis and right heart failure</ins>, <ins style="font-weight: bold; text-decoration: none;">named </ins>the <ins style="font-weight: bold; text-decoration: none;">condition as “cardiac negro” (black cardiac)</ins></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* In 1913 F. C. Arrillaga Syphilitic arteriosclerosis assigned as etiology </ins>of <ins style="font-weight: bold; text-decoration: none;">PH; changed </ins>the <ins style="font-weight: bold; text-decoration: none;">name </ins>of <ins style="font-weight: bold; text-decoration: none;">disease to “Ayerza’s Disease”</ins></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* In 1929 Werner Forssman demonstrated that </ins>it <ins style="font-weight: bold; text-decoration: none;">was possible </ins>to <ins style="font-weight: bold; text-decoration: none;">perform </ins>right <ins style="font-weight: bold; text-decoration: none;">sided catheterization </ins>in <ins style="font-weight: bold; text-decoration: none;">humans by performing </ins>catheterization <ins style="font-weight: bold; text-decoration: none;">on himself</ins></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Although </del>Ernst von Romberg<del style="font-weight: bold; text-decoration: none;">, a German physician</del>, described an autopsy <del style="font-weight: bold; text-decoration: none;">in 1891 as ‘pulmonary vascular sclerosis,’ it is only since 1995 with the introduction of intravenous epoprostenol that disease-specific targeted medical therapies for PAH have become available</del>. In <del style="font-weight: bold; text-decoration: none;">addition</del>, <del style="font-weight: bold; text-decoration: none;">significant advances in </del>the <del style="font-weight: bold; text-decoration: none;">treatment </del>of <del style="font-weight: bold; text-decoration: none;">PAH have occurred during </del>the <del style="font-weight: bold; text-decoration: none;">past decade, with six medical therapies now having received regulatory approval worldwide targeting the prostacyclin pathway, the nitric oxide pathway and the endothelin pathway [Figure 1]. Furthermore, ongoing clinical trials are evaluating novel therapeutic approaches based on scientific insights gleaned over the past decade in the pathobiology </del>of <del style="font-weight: bold; text-decoration: none;">PAH</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* </ins>In 1951 <ins style="font-weight: bold; text-decoration: none;">David </ins>Dresdale <ins style="font-weight: bold; text-decoration: none;">coined </ins>the <ins style="font-weight: bold; text-decoration: none;">term “primary </ins>pulmonary <ins style="font-weight: bold; text-decoration: none;">hypertension”</ins>, <ins style="font-weight: bold; text-decoration: none;">PPH </ins>for the first <ins style="font-weight: bold; text-decoration: none;">time</ins>.</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* </ins>In <ins style="font-weight: bold; text-decoration: none;">1956 Forssman</ins>, <ins style="font-weight: bold; text-decoration: none;">Cournand</ins>, <ins style="font-weight: bold; text-decoration: none;">Richards awarded Nobel Prize for their contributions to </ins>the <ins style="font-weight: bold; text-decoration: none;">discovery </ins>of <ins style="font-weight: bold; text-decoration: none;">circulatory and cardiopulmonary systems</ins></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">From a therapeutic standpoint, why had </del>it <del style="font-weight: bold; text-decoration: none;">taken from 1891 until 1995 </del>to <del style="font-weight: bold; text-decoration: none;">develop a safe and efficacious therapeutic modality for the treatment of PAH? [Figure 3] Although several reports of young women dying of </del>right <del style="font-weight: bold; text-decoration: none;">heart failure without a diagnosis were published </del>in <del style="font-weight: bold; text-decoration: none;">1940, it was not until pulmonary artery pressures could be recorded directly with the introduction of right heart </del>catheterization <del style="font-weight: bold; text-decoration: none;">that the physiology of the pulmonary circulation could be studied. </del>In 1951<del style="font-weight: bold; text-decoration: none;">, </del>Dresdale <del style="font-weight: bold; text-decoration: none;">tested </del>the <del style="font-weight: bold; text-decoration: none;">acute effects of tolzoline in a young woman with IPAH; the tolzoline caused a sudden decrease in pulmonary artery pressure and </del>pulmonary <del style="font-weight: bold; text-decoration: none;">vascular resistance without significant systemic effects. Unfortunately</del>, <del style="font-weight: bold; text-decoration: none;">no drugs were available at that time </del>for <del style="font-weight: bold; text-decoration: none;">chronic treatment. However, despite this, there remained little interest in PAH until the epidemic of the aminorex-induced PAH became apparent in the late 1960s. Prompted by </del>the <del style="font-weight: bold; text-decoration: none;">aminorex-induced PAH epidemic in 1973, the World Health Organization (WHO) held its </del>first <del style="font-weight: bold; text-decoration: none;">meeting in Geneva to assess what was known about IPAH and what remained unknown</del>. In <del style="font-weight: bold; text-decoration: none;">1981</del>, <del style="font-weight: bold; text-decoration: none;">the National Heart</del>, <del style="font-weight: bold; text-decoration: none;">Lung and Blood Institute of </del>the <del style="font-weight: bold; text-decoration: none;">National Institutes </del>of <del style="font-weight: bold; text-decoration: none;">Health supported a national registry of patients </del>with <del style="font-weight: bold; text-decoration: none;">IPAH, which resulted in several reports over </del>the <del style="font-weight: bold; text-decoration: none;">next decade describing clinical features </del>of <del style="font-weight: bold; text-decoration: none;">IPAH and its natural history. Interestingly, despite the fact that IPAH was an orphan disease</del>, <del style="font-weight: bold; text-decoration: none;">significant interest from the scientific community rapidly ensued</del>. <del style="font-weight: bold; text-decoration: none;">Advances </del>in the <del style="font-weight: bold; text-decoration: none;">understanding of the mechanisms involved in the pathobiology of IPAH and PAH associated with other conditions have focused on molecular biology, developmental biology and genetics</del>. <del style="font-weight: bold; text-decoration: none;">Together with epidemiological and </del>natural history <del style="font-weight: bold; text-decoration: none;">studies, collaborative efforts between the scientific community </del>and <del style="font-weight: bold; text-decoration: none;">industry have led to a surge in </del>clinical <del style="font-weight: bold; text-decoration: none;">trials over the past decade: since the approval </del>of <del style="font-weight: bold; text-decoration: none;">intravenous epoprostenol for </del>the <del style="font-weight: bold; text-decoration: none;">treatment of IPAH in 1995, the prostacyclin analogue treprostinil has been approved for continuous subcutaneous infusion in 2002 </del>and <del style="font-weight: bold; text-decoration: none;">for continuous intravenous infusion </del>in <del style="font-weight: bold; text-decoration: none;">2004. In addition, </del>the <del style="font-weight: bold; text-decoration: none;">prostacyclin analogue iloprost was approved in 2004 via inhalation. In 2001, bosentan, </del>an <del style="font-weight: bold; text-decoration: none;">endothelin ET A/ETB receptor antagonist, was the first oral therapy approved for the treatment </del>of PAH<del style="font-weight: bold; text-decoration: none;">; and sildenafil citrate, an oral phosphodiesterase type 5 inhibitor, </del>was <del style="font-weight: bold; text-decoration: none;">approved in 2005. In 2007, </del>the <del style="font-weight: bold; text-decoration: none;">oral ETA selective ERA ambrisentan was approved, </del>and <del style="font-weight: bold; text-decoration: none;">the oral ETA selective ERA sitaxsentan was approved in the EU</del>.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* In 1958 Paul Wood published Pulmonary Hypertension </ins>with <ins style="font-weight: bold; text-decoration: none;">Special Reference to </ins>the <ins style="font-weight: bold; text-decoration: none;">Vasoconstrictive Factor</ins></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* In 1965–1970s First PPH Epidemic Related to approval </ins>of <ins style="font-weight: bold; text-decoration: none;">Aminorex</ins>, .</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Prompted by the scientific insights from the 1990s, in </del>1998 <del style="font-weight: bold; text-decoration: none;">the second WHO meeting was held </del>on <del style="font-weight: bold; text-decoration: none;">the 25th anniversary </del>of <del style="font-weight: bold; text-decoration: none;">the original meeting</del>; <del style="font-weight: bold; text-decoration: none;">and with the dramatic advances over the next 5 years</del>, <del style="font-weight: bold; text-decoration: none;">the </del>3rd <del style="font-weight: bold; text-decoration: none;">WHO </del>Symposium on PAH <del style="font-weight: bold; text-decoration: none;">was held in 2003 and the </del>4th World Symposium on <del style="font-weight: bold; text-decoration: none;">PAH </del>in <del style="font-weight: bold; text-decoration: none;">2008. Based </del>on <del style="font-weight: bold; text-decoration: none;">the clinical trials to date, current consensus evidence-based guidelines for the treatment </del>of <del style="font-weight: bold; text-decoration: none;">PAH are shown in [Figure 4]. What have we been able to achieve? The disease-specific PAH therapies</del>, <del style="font-weight: bold; text-decoration: none;">currently available </del>in <del style="font-weight: bold; text-decoration: none;">conjunction with anticoagulant, diuretic, digitalis and oxygen therapy, have improved exercise capacity, functional capacity, time to clinical worsening, hemodynamic parameters, overall quality </del>of <del style="font-weight: bold; text-decoration: none;">life and survival. However, PAH remains </del>a <del style="font-weight: bold; text-decoration: none;">devastating, life-threatening disorder. In more than 50% </del>of <del style="font-weight: bold; text-decoration: none;">patients, exercise capacity remains significantly limited</del>, <del style="font-weight: bold; text-decoration: none;">approximately 50% </del>of <del style="font-weight: bold; text-decoration: none;">patients remain WHO functional class III or IV, PAH patients continue to have frequent hospitalizations for PAH, </del>right heart <del style="font-weight: bold; text-decoration: none;">function remains significantly impaired in most patients</del>, <del style="font-weight: bold; text-decoration: none;">quality of life is suboptimal </del>and <del style="font-weight: bold; text-decoration: none;">despite an increase in survival for functional class III and IV patients with IPAH from a predicted survival </del>of <del style="font-weight: bold; text-decoration: none;">33% (based on the NIH Registry) to 63% with our current therapeutic modalities, the outlook is far from ideal; we need to continue to aggressively pursue furthering our understanding of PAH if we ever hope to give these patients a near-normal life.</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* In 1973 1st WHO Meeting </ins>in <ins style="font-weight: bold; text-decoration: none;">PH </ins>the <ins style="font-weight: bold; text-decoration: none;">landmark meeting about PPH; provided recommendations for future directions</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* In 1981 PPH Registry landmark multi-center U.S</ins>. <ins style="font-weight: bold; text-decoration: none;">study characterizing </ins>natural history and clinical <ins style="font-weight: bold; text-decoration: none;">features </ins>of <ins style="font-weight: bold; text-decoration: none;">PPH</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* In 1996–1970s Second PPH Epidemic </ins>the <ins style="font-weight: bold; text-decoration: none;">association between anorexigens </ins>and <ins style="font-weight: bold; text-decoration: none;">PH was first identified </ins>in the <ins style="font-weight: bold; text-decoration: none;">1960s when </ins>an <ins style="font-weight: bold; text-decoration: none;">epidemic </ins>of PAH <ins style="font-weight: bold; text-decoration: none;">occurred in Europe that </ins>was <ins style="font-weight: bold; text-decoration: none;">linked to </ins>the <ins style="font-weight: bold; text-decoration: none;">anorexigens such as fenfluramine </ins>and <ins style="font-weight: bold; text-decoration: none;">dexfenfluramine </ins>.</div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* In </ins>1998 <ins style="font-weight: bold; text-decoration: none;">2nd World Symposium </ins>on <ins style="font-weight: bold; text-decoration: none;">PH formation of Evian Classification </ins>of <ins style="font-weight: bold; text-decoration: none;">PH</ins>; <ins style="font-weight: bold; text-decoration: none;">introduction of term “pulmonary arterial hypertension”</ins>, <ins style="font-weight: bold; text-decoration: none;">PAH</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* In 2003 </ins>3rd <ins style="font-weight: bold; text-decoration: none;">World </ins>Symposium on <ins style="font-weight: bold; text-decoration: none;">PH venice Classification; idiopathic </ins>PAH <ins style="font-weight: bold; text-decoration: none;">introduced to replace term PPH</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* In 2008 </ins>4th World Symposium on <ins style="font-weight: bold; text-decoration: none;">PH Dana Point Classification; modification of genetic category, among others </ins>in <ins style="font-weight: bold; text-decoration: none;">Group 1</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* In 2013 5th World Symposium </ins>on <ins style="font-weight: bold; text-decoration: none;">PH Nice Classification; further modifications </ins>of <ins style="font-weight: bold; text-decoration: none;">genetic category</ins>, <ins style="font-weight: bold; text-decoration: none;">among others </ins>in <ins style="font-weight: bold; text-decoration: none;">Group 1</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* In 2014 International Right Heart Failure Foundation Working Group development </ins>of a <ins style="font-weight: bold; text-decoration: none;">comprehensive nomenclature </ins>of <ins style="font-weight: bold; text-decoration: none;">right heart failure: defining distinction between right heart failure and right ventricular failure</ins>, <ins style="font-weight: bold; text-decoration: none;">components </ins>of right heart <ins style="font-weight: bold; text-decoration: none;">system</ins>, and <ins style="font-weight: bold; text-decoration: none;">definition </ins>of <ins style="font-weight: bold; text-decoration: none;">right heart failure</ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==References==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==References==</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{{reflist|2}}</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{{reflist|2}}</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;"></del></div></td><td colspan="2" class="diff-side-added"></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Category:Pulmonology]]</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Category:Pulmonology]]</div></td></tr>
</table>
Ajay Gade
https://www.wikidoc.org/index.php?title=Pulmonary_hypertension_Historical_Perspective&diff=1450306&oldid=prev
Ajay Gade: /* Historical Perspective */
2018-03-01T18:36:33Z
<p><span dir="auto"><span class="autocomment">Historical Perspective</span></span></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 18:36, 1 March 2018</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l9">Line 9:</td>
<td colspan="2" class="diff-lineno">Line 9:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>Prior to the development of disease-specific targeted PAH therapies, the median survival for subjects diagnosed with IPAH was approximately 2.8 years. However, 2.8 years likely underestimates current survival as the course of the disease has been favorably altered by therapeutic advances since that report from the 1980s. Prognosis is also dependent on the underlying etiology of the disease. The prognosis for patients with PAH associated with connective tissue disease appears to be worse than for those with IPAH. Estimates for 2-year survival in scleroderma patients with associated PAH are 40% compared with 48% for 3-year survival in patients with IPAH. Survival in patients with HIV-associated PAH is similar to patients with IPAH. With current HIV therapies, most of the deaths in patients with HIV and associated PAH are now attributed to PAH.</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>Prior to the development of disease-specific targeted PAH therapies, the median survival for subjects diagnosed with IPAH was approximately 2.8 years. However, 2.8 years likely underestimates current survival as the course of the disease has been favorably altered by therapeutic advances since that report from the 1980s. Prognosis is also dependent on the underlying etiology of the disease. The prognosis for patients with PAH associated with connective tissue disease appears to be worse than for those with IPAH. Estimates for 2-year survival in scleroderma patients with associated PAH are 40% compared with 48% for 3-year survival in patients with IPAH. Survival in patients with HIV-associated PAH is similar to patients with IPAH. With current HIV therapies, most of the deaths in patients with HIV and associated PAH are now attributed to PAH.</div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">Although Ernst von Romberg, a German physician, described an autopsy in 1891 as ‘pulmonary vascular sclerosis,’ it is only since 1995 with the introduction of intravenous epoprostenol that disease-specific targeted medical therapies for PAH have become available. In addition, significant advances in the treatment of PAH have occurred during the past decade, with six medical therapies now having received regulatory approval worldwide targeting the prostacyclin pathway, the nitric oxide pathway and the endothelin pathway [Figure 1]. Furthermore, ongoing clinical trials are evaluating novel therapeutic approaches based on scientific insights gleaned over the past decade in the pathobiology of PAH</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">From a therapeutic standpoint, why had it taken from 1891 until 1995 to develop a safe and efficacious therapeutic modality for the treatment of PAH? [Figure 3] Although several reports of young women dying of right heart failure without a diagnosis were published in 1940, it was not until pulmonary artery pressures could be recorded directly with the introduction of right heart catheterization that the physiology of the pulmonary circulation could be studied. In 1951, Dresdale tested the acute effects of tolzoline in a young woman with IPAH; the tolzoline caused a sudden decrease in pulmonary artery pressure and pulmonary vascular resistance without significant systemic effects. Unfortunately, no drugs were available at that time for chronic treatment. However, despite this, there remained little interest in PAH until the epidemic of the aminorex-induced PAH became apparent in the late 1960s. Prompted by the aminorex-induced PAH epidemic in 1973, the World Health Organization (WHO) held its first meeting in Geneva to assess what was known about IPAH and what remained unknown. In 1981, the National Heart, Lung and Blood Institute of the National Institutes of Health supported a national registry of patients with IPAH, which resulted in several reports over the next decade describing clinical features of IPAH and its natural history. Interestingly, despite the fact that IPAH was an orphan disease, significant interest from the scientific community rapidly ensued. Advances in the understanding of the mechanisms involved in the pathobiology of IPAH and PAH associated with other conditions have focused on molecular biology, developmental biology and genetics. Together with epidemiological and natural history studies, collaborative efforts between the scientific community and industry have led to a surge in clinical trials over the past decade: since the approval of intravenous epoprostenol for the treatment of IPAH in 1995, the prostacyclin analogue treprostinil has been approved for continuous subcutaneous infusion in 2002 and for continuous intravenous infusion in 2004. In addition, the prostacyclin analogue iloprost was approved in 2004 via inhalation. In 2001, bosentan, an endothelin ET A/ETB receptor antagonist, was the first oral therapy approved for the treatment of PAH; and sildenafil citrate, an oral phosphodiesterase type 5 inhibitor, was approved in 2005. In 2007, the oral ETA selective ERA ambrisentan was approved, and the oral ETA selective ERA sitaxsentan was approved in the EU.</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">Prompted by the scientific insights from the 1990s, in 1998 the second WHO meeting was held on the 25th anniversary of the original meeting; and with the dramatic advances over the next 5 years, the 3rd WHO Symposium on PAH was held in 2003 and the 4th World Symposium on PAH in 2008. Based on the clinical trials to date, current consensus evidence-based guidelines for the treatment of PAH are shown in [Figure 4]. What have we been able to achieve? The disease-specific PAH therapies, currently available in conjunction with anticoagulant, diuretic, digitalis and oxygen therapy, have improved exercise capacity, functional capacity, time to clinical worsening, hemodynamic parameters, overall quality of life and survival. However, PAH remains a devastating, life-threatening disorder. In more than 50% of patients, exercise capacity remains significantly limited, approximately 50% of patients remain WHO functional class III or IV, PAH patients continue to have frequent hospitalizations for PAH, right heart function remains significantly impaired in most patients, quality of life is suboptimal and despite an increase in survival for functional class III and IV patients with IPAH from a predicted survival of 33% (based on the NIH Registry) to 63% with our current therapeutic modalities, the outlook is far from ideal; we need to continue to aggressively pursue furthering our understanding of PAH if we ever hope to give these patients a near-normal life.</ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==References==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==References==</div></td></tr>
</table>
Ajay Gade